Valuation: Control Bionics Limited

Market Cap 30.49M 21.14M 18.48M 16.99M 15.83M 30.03M 2.01B 204M 79.27M 990M 79.36M 77.66M 3.41B P/E 2024
-1.4x
P/E 2025 -1.3x
Enterprise Value 30.25M 20.98M 18.34M 16.85M 15.71M 29.8M 2B 202M 78.65M 982M 78.74M 77.05M 3.38B EV / Sales 2024
1.92x
EV / Sales 2025 1.4x
Free-Float
47.41%
Yield 2024 *
-
Yield 2025 -
1 day-0.67%
1 week-9.76%
1 month+25.42%
3 months+23.33%
6 months+21.31%
Current year+21.31%
1 week 0.07
Extreme 0.071
0.09
1 month 0.07
Extreme 0.07
0.1
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.74
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 19/01/2023
Director of Finance/CFO - 13/05/2024
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman - 01/12/2025
Chairman 66 19/11/2025
Director/Board Member - 19/01/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.67%-9.76%+131.25%-14.94% 21.14M
-1.95%+1.16%+3.00%-28.72% 16.36B
+5.89%+23.51%+44.56%+95.19% 1.78B
+0.39%+32.34%-39.55%-78.08% 1.24B
+0.06%+3.85%-28.59%+34.44% 1.14B
+1.31%+4.95%-25.86%-53.39% 640M
+0.21%+3.42%-38.49%-58.09% 582M
-0.66%+3.11%+20.57%-55.49% 447M
+1.79%+0.16%-55.37%-60.09% 382M
+2.52%+7.65%-20.35%-17.75% 362M
Average +0.89%+5.88%-0.88%-23.69% 2.3B
Weighted average by Cap. -0.81%+4.50%-0.38%-20.93%

Financials

2024 2025
Net sales 5.35M 3.71M 3.24M 2.98M 2.78M 5.27M 353M 35.79M 13.91M 174M 13.93M 13.63M 598M 6.14M 4.26M 3.73M 3.42M 3.19M 6.05M 406M 41.1M 15.98M 199M 16M 15.65M 687M
Net income -5.91M -4.1M -3.59M -3.3M -3.07M -5.83M -391M -39.56M -15.38M -192M -15.39M -15.06M -661M -6.11M -4.24M -3.7M -3.4M -3.17M -6.02M -403M -40.86M -15.88M -198M -15.9M -15.56M -683M
Net Debt -96.95K -67.23K -58.78K -54.02K -50.35K -95.5K -6.4M -648K -252K -3.15M -252K -247K -10.84M -237K -165K -144K -132K -123K -234K -15.67M -1.59M -617K -7.7M -618K -604K -26.54M
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
03/07/26 $0.0740 -0.67% 79,459
02/07/26 $0.0745 +3.47% 178,494
01/07/26 $0.0720 -2.70% 837,811
30/06/26 $0.0740 -5.13% 630,575
29/06/26 $0.0780 -4.88% 499,206

Annual profits - Rate of surprise